Skip to main content
SpringerLink
Log in

What are the Alternatives to Increasing Inhaled Corticosteroids for the Long Term Control of Asthma?

  • Therapy in Practice
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

The Global Initiative for Asthma (GINA) guidelines stated the therapeutic goals for the management of asthma and, through a stepwise approach to treatment, defined the various grades of asthma severity and the therapeutic options available to the clinician at each step. This article considers the options at step 3; the management of a patient with poorly controlled asthma who is already taking low-dose inhaled corticosteroids.

Before considering a change in therapy, the clinician should rule out alternative diagnoses, confirm compliance with treatment, explore potential exacerbants in the patient’s environment and, where possible, remove them. If a change in medication is necessary, the choice of drug will depend on the therapeutic goal that needs to be achieved. If the most important goal is the control of symptoms and optimisation of lung function, most studies support the addition of a long-acting β2-agonist to low dose inhaled corticosteroids. If recurrent severe exacerbations are a major feature of the poor control, increasing the dosage of inhaled corticosteroids may be most effective. The addition of a leukotriene antagonist may be the best choice if exercise-induced symptoms are prominent or in the setting of aspirin-sensitive asthma.

General recommendations supported by the findings of large therapeutic trials do not allow for significant variability in the individual response to a particular drug. Receptor polymorphisms have recently been discovered that may account for variability in the response to β2-agonists and leukotriene receptor antagonists. However, until more is known about the reasons behind this variability, a therapeutic trial may be the most effective way of determining the best drug for an individual patient.

One of the key developments in asthma over the past decade has been the acceptance of the concept of asthma as a chronic inflammatory disorder of the airways. However, the long term significance of this inflammation is not clear and the importance of control of inflammation beyond the suppression of symptoms, reduction of exacerbation frequency and the optimisation of lung function has not been established.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Table III
Fig. 2
Fig. 3
Table IV

Similar content being viewed by others

References

  1. International consensus report on diagnosis and management of asthma. NIH Publication 92. Bthesda (MD): National Heart, Lung and Blood Institute, 1992

    Google Scholar 

  2. Spector SL, Kinsman R, Mawhinney H, et al. Compliance of patients with asthma with an experimental aerosolized medication: implications for controlled clinical trials. J Allergy Clin Immunol 1986; 77: 65–70

    Article  CAS  PubMed  Google Scholar 

  3. Kelloway JS, Wyatt RA, Adlis SA. Comparison of patients’ compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 1994; 154: 1349–52

    Article  CAS  PubMed  Google Scholar 

  4. Partridge MR. Delivering optimal care to the person with asthma: what are the key components and what do we mean by patient education? Eur Resp J 1995; 8: 298–305

    Article  CAS  Google Scholar 

  5. Flood-Page P, Partridge M. Asthma: a changing perspective on management. Curr Anaesth Crit Care 1996; 7: 260–5

    Article  Google Scholar 

  6. Dockery DW, Pope CA. Acute respiratory effects of particulate pollution. Annu Rev Public Health 1994; 15: 107–32

    Article  CAS  PubMed  Google Scholar 

  7. Harving H, Korsgaard J, Dahl R. Clinical efficacy of reduction in house-dust mite exposure in specially designed, mechanically ventilated “healthy homes”. Allergy 1994; 49: 866–70

    Article  CAS  PubMed  Google Scholar 

  8. Zeiger RS. Breast feeding and dietary avoidance In: DeWeck A, Sampson H, editors. Intestinal immunology and food allergy. Nestle Nutrition Workshop Series 34. New York: Raven Press, 1995: 203–22

    Google Scholar 

  9. Woodcock A, editor. Asthma and the environment: proceedings of a Symposium held on November 7–8, 1996; 1996 Nov 7–8; Wiesbaden. Eur Respir Rev 1998 Apr; 8 (53): 131-182

  10. Thorsson L, Edsbacker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 1994; 7: 1839–44

    Article  CAS  PubMed  Google Scholar 

  11. Melchor R, Biddiscombe MF, Mak VH, et al. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 1993; 48:506–11

    Article  CAS  PubMed  Google Scholar 

  12. Selroos O, Pietinalho A, Riska H. Delivery devices for inhaled asthma medication — clinical implications of differences in effectiveness. Clin Immunother 1986; 6: 273–99

    Article  Google Scholar 

  13. Haahtela T, Jarvinen M, Kava T, et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325: 388–92

    Article  CAS  PubMed  Google Scholar 

  14. vanEssen-Zandvliet EE, Hughes MD, Waalkens HJ, et al. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group. Am Rev Respir Dis 1992; 146: 547–54

    PubMed  Google Scholar 

  15. Smith MJ, Hodson ME. High-dose beclomethasone inhaler in the treatment of asthma. Lancet 1983; I: 265–69

    Article  Google Scholar 

  16. Boe J, Rosenhall L, Alton M, et al. Comparison of dose-response effects of inhaled beclomethasone dipropionate and budesonide in the management of asthma. Allergy 1989; 44: 349–55

    Article  CAS  PubMed  Google Scholar 

  17. Barnes NC, Marone G, Di Maria GU, et al. A comparison of fluticasone propionate, 1mg daily, with beclomethasone dipropionate, 2mg daily, in the treatment of severe asthma. International Study Group. Eur Respir J 1993; 6: 877–85

    CAS  PubMed  Google Scholar 

  18. Egan J, Kalra S, Adams J. A randomised double blind study comparing the effects of beclomethasone dipropionate 2000 mcg/day versus fluticasone propionate 1000 mcg/day on bone density over 2 years. Thorax 1999; 50Suppl. 2: A78

    Google Scholar 

  19. Hanania NA, Chapman KR, Sturtridge WC, et al. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol 1995; 96 (5 Pt 1):571–9

    Article  CAS  PubMed  Google Scholar 

  20. Hughes JA, Conry BG, Male SM, et al. One year prospective open study of the effect of high inhaled steroids, fluticasone propionate, and budesonide on bone markers and bone mineral density. Thorax 1999; 54: 223–9

    Article  CAS  PubMed  Google Scholar 

  21. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998; 157: S1–53

    CAS  PubMed  Google Scholar 

  22. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts [see comments]. N Engl J Med 1997; 337: 8–14

    Article  CAS  PubMed  Google Scholar 

  23. Garbe E, LeLorier J, Boivin JF, et al. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997; 277: 722–7

    Article  CAS  PubMed  Google Scholar 

  24. Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma [see comments]. Lancet 1990; 336: 1391–6

    Article  CAS  PubMed  Google Scholar 

  25. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group [published erratum appears in N Engl J Med 1998 Jan 8; 338 (2): 139]. N Engl J Med 1997; 337: 1405–11

    Article  CAS  PubMed  Google Scholar 

  26. Hummel S, Lehtonen L. Comparison of oral-steroid sparing by high-dose and low-dose inhaled steroid in maintenance treatment of severe asthma [see comments]. Lancet 1992; 340(8834-8835): 1483–7

    Article  CAS  PubMed  Google Scholar 

  27. Wasserman SI, Gross GN, Schoenwetter WF, et al. A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma. J Asthma 1996; 33(4): 265–74

    Article  CAS  PubMed  Google Scholar 

  28. vanSchayck CP, Dompeling E, van Herwaarden CL, et al. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study [see comments]. BMJ 1991; 303: 1426–31

    Article  PubMed  Google Scholar 

  29. Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344: 219–24

    Article  CAS  PubMed  Google Scholar 

  30. Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481–8

    CAS  PubMed  Google Scholar 

  31. Sears MR, Taylor D. The beta2 agonist controversy. Observations, explanations, and relationship to asthma epidemiology. Drug Saf 1994; 2: 259–83

    Article  Google Scholar 

  32. Bhagat R, Kalra S, Swystun VA, et al. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 1995; 108: 1235–9

    Article  CAS  PubMed  Google Scholar 

  33. Nelson JA, Strauss L, Skowronski M, et al. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med 1998; 339: 141–6

    Article  CAS  PubMed  Google Scholar 

  34. Newnham DM, Grove A, McDevitt DG, et al. Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax 1995; 50: 497–504

    Article  CAS  PubMed  Google Scholar 

  35. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 1998; 279: 1181–6

    Article  CAS  PubMed  Google Scholar 

  36. Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998; 158: 1213–20

    Article  CAS  PubMed  Google Scholar 

  37. Fish JE, Kemp JP, Lockey RF, et al. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group. Clin Ther 1997; 19: 675–90

    Article  CAS  PubMed  Google Scholar 

  38. Tamaoki J, Kondo M, Sakae N, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid; The Tokyo Joshe-Idai Asthma Research Group. Am J Respir Crit Care Med 1997; 155: A662

    Google Scholar 

  39. Israel E, Cohn J, Dube L, et al. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. Arandomized controlled trial. Zileuton Clinical Trial Group. JAMA 1996; 275: 931–6

    Article  CAS  PubMed  Google Scholar 

  40. O’Shaughnessy KM, Wellings R, Gillies B, et al. Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion [see comments]. Am Rev Respir Dis 1993; 147: 1472–6

    PubMed  Google Scholar 

  41. Nayak AS, Anderson P, Charous BL, et al. Equivalence of adding zafirlukast versus double-dose inhaled corticosteroids in asthmatic patients symoptomatic on low-dose inhaled corticosteroids [abstract]. J Allergy Clin Immunol 1998; 101:1(Pt 2): S233

    Article  Google Scholar 

  42. Leff JA, Israel E, Noonan MJ, et al. Montelukast allows tapering on inhaled corticosteroids in asthmatic patients while maintaining stability. Am J Resp Crit Care Med 1997; 155: A976

    Google Scholar 

  43. Busse W, Nelson H, Wolfe J, et al. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol 1999; 103: 1075–80

    Article  CAS  PubMed  Google Scholar 

  44. Dahlen B, Kumlin M, Margolskee DJ, et al. The leukotrienereceptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J 1993; 6: 1018–26

    CAS  PubMed  Google Scholar 

  45. Cowburn AS, Sladek K, Soja J, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998; 101: 834–46

    Article  CAS  PubMed  Google Scholar 

  46. Dahlen B, Nizankowsa E, Szczeklik A, et al. Benefits from adding the 5-Lipoxygenase inhibitor Zileutin to conventional therapy in aspirin sensitive asthmatics. Am J Resp Crit Care Med 1998; 157: 1187–94

    CAS  PubMed  Google Scholar 

  47. Turpin JA, Edelman JM, DeLucca PT, et al. Chronic administration of montelukast is superior to inhaled salmeterol in the prevention of exercise induced bronchospasm. Am J Respir Crit Care Med 1998; 157 (Pt 2): A456

    Google Scholar 

  48. Zeneca UK Ltd. Accolate UK Data Sheet. Data on file 1998.

  49. Merck Sharp and Dohme. Singulair Data Sheet. Data on file 1998

  50. Wechsler ME, Finn D, Jordan M, et al. Montelukast and the Churg-Strauss syndrome. Am J Respir Crit Care Med 1999; 159:A641

    Google Scholar 

  51. Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticos-teroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998; 279: 455–57

    Article  CAS  PubMed  Google Scholar 

  52. Liu MC, Dube LM, Lancaster J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. J Allergy Clin Immunol 1996; 98: 859–71

    Article  CAS  PubMed  Google Scholar 

  53. Weinberger M, Hendeles L. Theophylline in asthma. N Engl J Med 1996; 334: 1380–8

    Article  CAS  PubMed  Google Scholar 

  54. Sullivan P, Bekir S, Jaffar Z, et al. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma [published erratum appears in Lancet 1994; 343: 1512]. Lancet 1994; 343: 1006–8

    Article  CAS  PubMed  Google Scholar 

  55. Evans DJ, Taylor DA, Zetterstrom O, et al. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997; 337: 1412–8

    Article  CAS  PubMed  Google Scholar 

  56. Crompton GK, Ayres JG, Basran G, et al. Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids. Am J Respir Crit Care Med 159: 824-8

  57. Vignola AM, Chanez P, Campbell AM, et al. Airway inflammation in mild intermittent and in persistent asthma. Am J Respir Crit Care Med 1998; 157: 403–9

    CAS  PubMed  Google Scholar 

  58. Phunek P, Roche WR, Turzekora J, et al. Eosinophilic inflammation in the bronchial mucosa of children with bronchial asthma. Eur J Respir Dis 1997; 10: 160S

    Google Scholar 

  59. Peat JK, Woolcock AJ, Cullen K. Rate of decline of lung function in subjects with asthma. Eur J Respir Dis 1987; 70: 171–9

    CAS  PubMed  Google Scholar 

  60. Lange P, Parner J, Vestbo J, et al. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998; 339: 1194–1200

    Article  CAS  PubMed  Google Scholar 

  61. Hoshino M, Nakamura Y, Sim JJ. Expression of growth factors and remodelling of the airway wall in bronchial asthma. Thorax 1998; 53: 21–7

    Article  CAS  PubMed  Google Scholar 

  62. Chetta A, Foresi A, Del Donno M, et al. Airways remodeling is a distinctive feature of asthma and is related to severity of disease. Chest 1997; 111: 852–7

    Article  CAS  PubMed  Google Scholar 

  63. Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992; 90: 32–42

    Article  CAS  PubMed  Google Scholar 

  64. Djukanovic R, Wilson JW, Holgate ST. Effect of an inhaled steroid on airway inflammation and symptoms of asthma. Am Rev Respir Dis 1999; 145: 674–99

    Google Scholar 

  65. Calhoun WJ, Lavins BJ, Minkwitz MC, et al. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge. Am J Respir Crit Care Med 1998; 157: 1381–9

    CAS  PubMed  Google Scholar 

  66. Leff JA, Pizzichini E, Efthimiadis A, et al. Effect of montelukast on airway eosinophilic inflammation in mildly controlled asthma: a randomised placebo control study. Am J Respir Crit Care Med 1997; 155: A977

    Google Scholar 

  67. Nakamura Y, Hoshino M, Sim JJ, et al. Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax 1998; 53: 835–41

    Article  CAS  PubMed  Google Scholar 

  68. Gardiner PV, Ward C, Booth H, et al. Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am J Respir Crit Care Med 1994; 150: 1006–11

    CAS  PubMed  Google Scholar 

  69. McIvor RA, Pizzichini E, Turner MO, et al. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 158(3): 924-30

  70. Juniper EF, Kline PA, Vanzieleghem MA, et al. Effect of longterm treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990; 42: 832–6

    Google Scholar 

  71. Haahtela T, Jarvinen M, Kava T, et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325: 388–92

    Article  CAS  PubMed  Google Scholar 

  72. Selroos O, Pietinalho A, Lofroos AB, et al. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest 1995; 108: 1228–34

    Article  CAS  PubMed  Google Scholar 

  73. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88: 373–81

    Article  CAS  PubMed  Google Scholar 

  74. Olivieri D, Chetta A, Del Donno M, et al. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am J Respir Crit Care Med 155: 1864-71

  75. Laitinen A, Altraja A, Kampe M, et al. Tenascin is increased in airway basement membrane of asthmatics and decreased by an inhaled steroid. Am J Respir Crit Care Med 1997; 156: 951–8

    CAS  PubMed  Google Scholar 

  76. Sont JK, Willems LN, Bel EH, et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999; 159 (4 Pt 1): 1043–5177

    CAS  PubMed  Google Scholar 

  77. Jeffery PK, Godfrey RW, Adelroth E, et al. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. Am Rev Respir Dis 1992; 145: 890–9

    CAS  PubMed  Google Scholar 

  78. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/ Beclomethasone Study Group. Ann Intern Med 1999; 130: 487–95

    CAS  PubMed  Google Scholar 

  79. Green SA, Turki J, Innis M, et al. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994; 33: 9414–9

    Article  CAS  PubMed  Google Scholar 

  80. Turki J, Pak J, Green SA, et al. Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and non-nocturnal asthma. Evidence that Glyl6 correlates with the nocturnal phenotype. J Clin Invest 1995; 95: 1635–41

    Article  CAS  PubMed  Google Scholar 

  81. Lipworth BJ, Hall IP, Aziz I, et al. Beta2-adrenoceptor polymorphism and bronchoprotective sensitivity with regular short- and long-acting beta2-agonist therapy. Clin Sci 1999; 96: 253–9

    Article  CAS  PubMed  Google Scholar 

  82. Hall IP, Wheatley A, Wilding P, et al. Association of Glu 27 beta 2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet 1995; 345: 1213–4

    Article  CAS  PubMed  Google Scholar 

  83. Drazen JM, Yandava CN, Dube L, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genetics 1999; 22(2): 168–70

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. London Chest Hospital, The Royal Hospitals NHS Trust, Bonner Road, London, E2 9JX, England

    Patrick Flood-Page & Neil C. Barnes

Authors
  1. Patrick Flood-Page
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neil C. Barnes
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Flood-Page, P., Barnes, N.C. What are the Alternatives to Increasing Inhaled Corticosteroids for the Long Term Control of Asthma?. BioDrugs 15, 185–198 (2001). https://doi.org/10.2165/00063030-200115030-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200115030-00005

Keywords

Search

Navigation